Loading
Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial.
Approved by the NMPA in March 2020 for EGFR T790M-positive NSCLC after prior EGFR inhibitors and in December 2021 for first-line EGFR-mutant NSCLC on AENEAS (429 patients: median progression-free survival 19.3 versus 9.9 months with gefitinib, hazard ratio 0.46). It has become one of the most prescribed targeted drugs in China after NRDL listing and is under evaluation in Europe. Hansoh is testing it after chemoradiotherapy in stage III disease and in combination regimens.
Irreversible third-generation EGFR inhibitor selective for sensitising and T790M mutations over wild-type EGFR; a cyclopropyl modification of the osimertinib scaffold. Connects to EGFR.
1.Aumolertinib slips into a pocket on EGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2020 | EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy |
| China | 2021 | First-line EGFR exon 19 deletion or L858R NSCLC (AENEAS) |
| EU | 2026 | Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Aumolertinib" OR ABSTRACT:"Aumolertinib" OR TITLE:"Ameile" OR ABSTRACT:"Ameile" OR TITLE:"HS-10296" OR ABSTRACT:"HS-10296" OR TITLE:"almonertinib" OR ABSTRACT:"almonertinib" OR TITLE:"Aumseqa" OR ABSTRACT:"Aumseqa" OR TITLE:"Almonertinib" OR ABSTRACT:"Almonertinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Aumolertinib, not a curated reading list.
Shares AENEAS, EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M), RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.